Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹3,749 Cr revenue.
COGS 37.1%, employees 15.5%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 59.8%▲ | 10.5% |
| ROCE | 70.0%▲ | 13.8% |
| Net Margin | 25.8%▲ | 8.7% |
| EBITDA Margin | 37.0%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
| Rev Growth 3yr | 5.1%▼ | 5.8% |
| EPS Growth 3yr | 14.9%▲ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,801 Cr +1.4% | ₹3,749 Cr +8.6% | ₹3,454 Cr +6.2% | ₹3,252 Cr -0.8% | ₹3,278 Cr +2.5% | ₹3,199 Cr -0.8% | ₹3,224 Cr +3.1% | ₹3,128 Cr |
| Other Income | ₹150 Cr +2.9% | ₹146 Cr +19.0% | ₹123 Cr +21.8% | ₹101 Cr +32.8% | ₹76 Cr -31.5% | ₹111 Cr +40.0% | ₹79 Cr -22.8% | ₹102 Cr |
| Total Income | ₹3,951 Cr +1.4% | ₹3,895 Cr +8.9% | ₹3,576 Cr +6.7% | ₹3,352 Cr -0.0% | ₹3,354 Cr +1.3% | ₹3,309 Cr +0.2% | ₹3,303 Cr +2.3% | ₹3,230 Cr |
| COGS | ₹1,359 Cr -2.3% | ₹1,391 Cr +4.2% | ₹1,335 Cr +3.9% | ₹1,285 Cr -5.3% | ₹1,356 Cr +3.3% | ₹1,313 Cr +0.4% | ₹1,308 Cr -3.7% | ₹1,358 Cr |
| ₹2,580 Cr -2.3% | ₹2,640 Cr +0.9% | ₹2,617 Cr +4.0% | ₹2,515 Cr -2.8% | ₹2,586 Cr 0.0% | ₹2,586 Cr -2.6% | ₹2,656 Cr +3.1% | ₹2,576 Cr | |
| Profit Before Tax | ₹1,391 Cr +10.4% | ₹1,260 Cr +54.4% | ₹816 Cr -2.4% | ₹836 Cr +7.4% | ₹779 Cr +41.5% | ₹551 Cr +80.1% | ₹306 Cr -55.2% | ₹683 Cr |
| Exceptional Items | ₹21 Cr +339.7% | ₹5 Cr ↑ Recovery | (₹144 Cr) | (₹0.97 Cr) ↓ Decline | ₹12 Cr ↑ Recovery | (₹173 Cr) +49.5% | (₹341 Cr) ↓ Decline | ₹29 Cr |
| ₹370 Cr +11.5% | ₹332 Cr +46.9% | ₹226 Cr -1.1% | ₹229 Cr -42.6% | ₹398 Cr +107.1% | ₹192 Cr -9.5% | ₹213 Cr -10.4% | ₹237 Cr | |
| Net Profit | ₹1,021 Cr +10.1% | ₹928 Cr +57.2% | ₹590 Cr -3.4% | ₹611 Cr +60.4% | ₹381 Cr +6.3% | ₹358 Cr +284.3% | ₹93 Cr -79.1% | ₹445 Cr |
| Profit (Owners) | ₹1,021 Cr +10.1% | ₹928 Cr +57.2% | ₹590 Cr -3.4% | ₹611 Cr -64.0% | ₹1,695 Cr +373.2% | ₹358 Cr +284.3% | ₹93 Cr -79.1% | ₹445 Cr |
| Other Comprehensive Income | ₹2 Cr ↑ Recovery | (₹3 Cr) +36.2% | (₹4 Cr) +31.0% | (₹6 Cr) -226.5% | (₹2 Cr) +9.8% | (₹2 Cr) +48.5% | (₹4 Cr) +27.6% | (₹5 Cr) |
| EPS | ₹60.27 | ₹54.75 | ₹34.83 | ₹36.05 | ₹100.04 | ₹21.14 | ₹5.50 | ₹26.29 |
| Diluted Shares | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr | ₹17 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Letter for weblink for Annual Report '.
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Resignation of Director/KMP/SMP
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Cessation of Dr Simrat Sohal as Other of the company w.e.f. August 05, 2026.
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Transcript
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding a press release dated 0 , , titled "Press release ".
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Investor Presentation
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on Jun 30, 2026
GlaxoSmithKline Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 29-May-2026.
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2026, recommended Final Dividend of Rs. 57 per equity share.
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Schedule of meet
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication